202 related articles for article (PubMed ID: 33739915)
1. The implications of suboptimal year-1 outcomes with disease-modifying therapy in employees with multiple sclerosis.
Hersh CM; Brook RA; Beren IA; Rohrbacker NJ; Lebson L; Henke C; Phillips AL
J Med Econ; 2021; 24(1):479-486. PubMed ID: 33739915
[TBL] [Abstract][Full Text] [Related]
2. The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US.
Ivanova JI; Birnbaum HG; Samuels S; Davis M; Phillips AL; Meletiche D
Pharmacoeconomics; 2009; 27(8):681-91. PubMed ID: 19712010
[TBL] [Abstract][Full Text] [Related]
3. Absenteeism and health-benefit costs among employees with MS.
Brook RA; Rajagopalan K; Kleinman NL; Melkonian AK
Curr Med Res Opin; 2009 Jun; 25(6):1469-76. PubMed ID: 19422277
[TBL] [Abstract][Full Text] [Related]
4. Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.
Freeman L; Kee A; Tian M; Mehta R
Drugs Real World Outcomes; 2021 Dec; 8(4):497-508. PubMed ID: 34136997
[TBL] [Abstract][Full Text] [Related]
5. Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis.
Burks J; Marshall TS; Ye X
Clinicoecon Outcomes Res; 2017; 9():251-260. PubMed ID: 28496344
[TBL] [Abstract][Full Text] [Related]
6. Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US.
Ivanova JI; Bergman RE; Birnbaum HG; Phillips AL; Stewart M; Meletiche DM
J Med Econ; 2012; 15(3):601-9. PubMed ID: 22376190
[TBL] [Abstract][Full Text] [Related]
7. Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data.
Engmann NJ; Sheinson D; Bawa K; Ng CD; Pardo G
J Manag Care Spec Pharm; 2021 May; 27(5):639-649. PubMed ID: 33624535
[No Abstract] [Full Text] [Related]
8. The Clinical and Economic Impact of Employees Who Are Care Partners of Patients with Multiple Sclerosis by Disease Severity.
Hendin B; Brook RA; Beren IA; Kleinman N; Fink C; Phillips AL; Lobo C
J Health Econ Outcomes Res; 2023; 10(1):91-101. PubMed ID: 37069893
[No Abstract] [Full Text] [Related]
9. Productivity loss outcomes and costs among patients with cholangiocarcinoma in the United States: an economic evaluation.
Parasuraman S; Thiel E; Park J; Teschemaker A
J Med Econ; 2023; 26(1):454-462. PubMed ID: 36883994
[TBL] [Abstract][Full Text] [Related]
10. Impact of adherence to disease modifying therapies on long-term clinical and economic outcomes in multiple sclerosis: A claims analysis of real-world data.
Amezcua L; Livingston T; Hayward B; Zhou J; Williams MJ
Mult Scler Relat Disord; 2023 Sep; 77():104866. PubMed ID: 37487345
[TBL] [Abstract][Full Text] [Related]
11. Medication adherence with disease modifying treatments for multiple sclerosis among US employees.
Kleinman NL; Beren IA; Rajagopalan K; Brook RA
J Med Econ; 2010; 13(4):633-40. PubMed ID: 20958113
[TBL] [Abstract][Full Text] [Related]
12. Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs.
Birnbaum HG; Ivanova JI; Samuels S; Davis M; Cremieux PY; Phillips AL; Meletiche D
Curr Med Res Opin; 2009 Apr; 25(4):869-77. PubMed ID: 19232041
[TBL] [Abstract][Full Text] [Related]
13. Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis.
Kantor D; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
Clin Ther; 2020 Nov; 42(11):2136-2147.e3. PubMed ID: 33160682
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
[TBL] [Abstract][Full Text] [Related]
15. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
[TBL] [Abstract][Full Text] [Related]
16. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
Neuberger EE; Abbass IM; Jones E; Engmann NJ
Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
[TBL] [Abstract][Full Text] [Related]
17. The impact of persistence with therapy on inpatient admissions and emergency room visits in the US among patients with multiple sclerosis.
Thomas NP; Curkendall S; Farr AM; Yu E; Hurley D
J Med Econ; 2016; 19(5):497-505. PubMed ID: 26706292
[TBL] [Abstract][Full Text] [Related]
18. Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.
Bowen J; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
Adv Ther; 2020 Jul; 37(7):3163-3177. PubMed ID: 32436028
[TBL] [Abstract][Full Text] [Related]
19. Adherence and persistence to self-administered disease-modifying therapies in patients with multiple sclerosis: A multisite analysis.
Zuckerman AD; DeClercq J; Simonson D; Zagel AL; Turco E; Banks A; Wawrzyniak J; Rightmier E; Blevins A; Choi L
Mult Scler Relat Disord; 2023 Jul; 75():104738. PubMed ID: 37182475
[TBL] [Abstract][Full Text] [Related]
20. Costs and absence of HCV-infected employees by disease stage.
Baran RW; Samp JC; Walker DR; Smeeding JE; Young JW; Kleinman NL; Brook RA
J Med Econ; 2015; 18(9):691-703. PubMed ID: 26047262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
